Cargando…

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance

Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding during direct oral anticoagulant administration, which contributes to safety. In patients undergoing surgery with cardiopulmo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitaura, Atsuhiro, Iwamoto, Tatsushige, Hamasaki, Shinichi, Tsukimoto, Shota, Nakajima, Yasufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516723/
https://www.ncbi.nlm.nih.gov/pubmed/37746371
http://dx.doi.org/10.7759/cureus.44003
_version_ 1785109187464790016
author Kitaura, Atsuhiro
Iwamoto, Tatsushige
Hamasaki, Shinichi
Tsukimoto, Shota
Nakajima, Yasufumi
author_facet Kitaura, Atsuhiro
Iwamoto, Tatsushige
Hamasaki, Shinichi
Tsukimoto, Shota
Nakajima, Yasufumi
author_sort Kitaura, Atsuhiro
collection PubMed
description Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding during direct oral anticoagulant administration, which contributes to safety. In patients undergoing surgery with cardiopulmonary bypass because of heparin resistance, anesthesiologists are faced with a choice of anticoagulants. Herein, we experienced anesthesia for vascular prostheses with cardiopulmonary bypass for acute aortic dissection in a patient who had received andexanet alfa preoperatively. Heparin was initially used as the anticoagulant during cardiopulmonary bypass; however, despite the administration of large doses and antithrombin III preparations, anticoagulation was insufficient. Therefore, nafamostat mesilate was administered and sufficient anticoagulation was attained. The patient completed surgery under cardiopulmonary bypass, coagulation function was recovered shortly after withdrawal, and no obvious adverse effects were observed.
format Online
Article
Text
id pubmed-10516723
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105167232023-09-24 Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance Kitaura, Atsuhiro Iwamoto, Tatsushige Hamasaki, Shinichi Tsukimoto, Shota Nakajima, Yasufumi Cureus Anesthesiology Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding during direct oral anticoagulant administration, which contributes to safety. In patients undergoing surgery with cardiopulmonary bypass because of heparin resistance, anesthesiologists are faced with a choice of anticoagulants. Herein, we experienced anesthesia for vascular prostheses with cardiopulmonary bypass for acute aortic dissection in a patient who had received andexanet alfa preoperatively. Heparin was initially used as the anticoagulant during cardiopulmonary bypass; however, despite the administration of large doses and antithrombin III preparations, anticoagulation was insufficient. Therefore, nafamostat mesilate was administered and sufficient anticoagulation was attained. The patient completed surgery under cardiopulmonary bypass, coagulation function was recovered shortly after withdrawal, and no obvious adverse effects were observed. Cureus 2023-08-23 /pmc/articles/PMC10516723/ /pubmed/37746371 http://dx.doi.org/10.7759/cureus.44003 Text en Copyright © 2023, Kitaura et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Anesthesiology
Kitaura, Atsuhiro
Iwamoto, Tatsushige
Hamasaki, Shinichi
Tsukimoto, Shota
Nakajima, Yasufumi
Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
title Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
title_full Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
title_fullStr Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
title_full_unstemmed Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
title_short Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
title_sort successful nafamostat mesilate administration for andexanet alfa-induced heparin resistance
topic Anesthesiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516723/
https://www.ncbi.nlm.nih.gov/pubmed/37746371
http://dx.doi.org/10.7759/cureus.44003
work_keys_str_mv AT kitauraatsuhiro successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance
AT iwamototatsushige successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance
AT hamasakishinichi successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance
AT tsukimotoshota successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance
AT nakajimayasufumi successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance